Daratumumab, Venetoclax, and Azacitidine in Combination with HAA Regimen as Consolidation Chemotherapy for T-cell Acute Lymphoblastic Leukemia with High CD38 Expression
Lin-sen Feng1, Hui-yuan Li2, Ai Tang3, Meng-li Xu4, San-bin Wang41The Sixth Affiliated Hospital, Kunming Medical University, Yunnan, China; The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China; The People’s Hospital of Yuxi City, Department of Hematology, Yunnan, China; unming Medical University, School of General Practitioners, Yunnan, China2The First People’s Hospital of Yunnan Province, Department of Integrated TCM & Western Medicine, Yunnan, China
3Kunming Medical University, School of General Practitioners, Yunnan, China
4The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China
Corresponding Author: San-bin Wang, China
| TOOLS |
 Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author
Similar articles PubMed Google Scholar |